RecruitingPhase 4NCT06410352

Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome

Studying NON RARE IN EUROPE: Metabolic syndrome

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Medical Center, Kazakhstan
Principal Investigator
Kuat Oshakbayev, professor
University Medical Center, Kazakhstan
Intervention
Semaglutide, Empagliflozin(drug)
Enrollment
220 target
Eligibility
35-65 years · All sexes
Timeline
2024 – 2026

Study locations (1)

Collaborators

Nazarbayev University School of Medicine · Nazarbayev University · Astana Medical University · Public Association "Eurasian Society of Personalized Medicine" · Ministry of Science and Higher Education of the Republic of Kazakhstan

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06410352 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Metabolic syndrome

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Metabolic syndrome →

← Back to all trials